Komori
Governance4885MUROMACHI CHEMICALS INC.Pharmaceuticals

Corporate Governance Report 2026/08/28

Reports the corporate governance structure and internal procedures for the timely disclosure of financial results information, decisions and occurrences. Changes from the previous report are not stated in the body of the report.

Worth reading
43Recurring
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Committee3
Nomination and Compensation CommitteeRisk Management CommitteeCompliance Committee
Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
CommitteeNomination and Compensation Committee (percentage of outside members: Not disclosed), Risk Management Committee, Compliance Committee
Items this document does not state (6)
Number of directorsNumber of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholderChanges this time

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the corporate governance structure and timely disclosure procedures.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Governance Report 2026/08/28 | MUROMACHI CHEMICALS INC. (4885) timely disclosure | Komori